Document is current
Any future updates will be listed below
-
Authors
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
Galimard, Jacques-Emmanuel https://orcid.org/0000-0001-9102-4427
Pryce, Angharad
Bhoopalan, Senthil Velan https://orcid.org/0000-0002-1402-6549
Dalissier, Arnaud
Dalle, Jean-Hugues
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
Jubert, Charlotte
Mirci-Danicar, Oana
Kitra-Roussou, Vassiliki
Bertrand, Yves
Fagioli, Franca https://orcid.org/0000-0002-9257-900X
Rialland, Fanny https://orcid.org/0000-0002-3136-6270
Biffi, Alessandra
Wynn, Robert F. https://orcid.org/0000-0002-6046-8428
Michel, Gérard https://orcid.org/0000-0002-0018-5709
Tambaro, Francesco Paolo https://orcid.org/0000-0002-9145-3691
Al-Ahmari, Ali https://orcid.org/0000-0002-8732-5611
Tbakhi, Abdelghani
Furness, Caroline L.
Diaz, Miguel Angel
Sedlacek, Petr
Bodova, Ivana
Faraci, Maura https://orcid.org/0000-0001-5715-501X
Rao, Kanchan
Kleinschmidt, Katharina https://orcid.org/0000-0002-1447-7286
Petit, Arnaud https://orcid.org/0000-0001-8363-1622
Gibson, Brenda
Bhatt, Neel S. https://orcid.org/0000-0003-2033-1125
Kalwak, Krzysztof https://orcid.org/0000-0003-1174-5799
Corbacioglu, Selim https://orcid.org/0000-0003-1070-8486
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA021765)
American Lebanese Syrian Associated Charities (NA)
- License Information
-
More Information
Article History
Received: 29 October 2023
Revised: 14 December 2023
Accepted: 2 January 2024
First Online: 15 January 2024
Competing interests
: AS has received consultant fees from Spotlight Therapeutics, Medexus Inc., Vertex Pharmaceuticals, Sangamo Therapeutics, and Editas Medicine. He is a medical monitor for an RCI BMT CSIDE clinical trial for which he receives financial compensation. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. AS is the St. Jude Children’s Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907), and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trial, which includes salary support paid to AS’s institution. AS has no direct financial interest in these therapies.
